Last reviewed · How we verify
Centanafadine QD XR
Centanafadine QD XR is a Small molecule drug developed by Otsuka Pharmaceutical Development & Commercialization, Inc.. It is currently in Phase 1 development. Also known as: EB-1020.
At a glance
| Generic name | Centanafadine QD XR |
|---|---|
| Also known as | EB-1020 |
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects (PHASE1)
- A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine (PHASE1)
- A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (PHASE1)
- A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD (PHASE2, PHASE3)
- A Long-term Trial of EB-1020 in Pediatric Patients With ADHD (PHASE3)
- A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels (PHASE1)
- P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety (PHASE3)
- A Long-term Trial of EB-1020 in Adult Patients With ADHD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Centanafadine QD XR CI brief — competitive landscape report
- Centanafadine QD XR updates RSS · CI watch RSS
- Otsuka Pharmaceutical Development & Commercialization, Inc. portfolio CI
Frequently asked questions about Centanafadine QD XR
What is Centanafadine QD XR?
Centanafadine QD XR is a Small molecule drug developed by Otsuka Pharmaceutical Development & Commercialization, Inc..
Who makes Centanafadine QD XR?
Centanafadine QD XR is developed by Otsuka Pharmaceutical Development & Commercialization, Inc. (see full Otsuka Pharmaceutical Development & Commercialization, Inc. pipeline at /company/otsuka-pharmaceutical-development-commercialization-inc).
Is Centanafadine QD XR also known as anything else?
Centanafadine QD XR is also known as EB-1020.
What development phase is Centanafadine QD XR in?
Centanafadine QD XR is in Phase 1.
Related
- Manufacturer: Otsuka Pharmaceutical Development & Commercialization, Inc. — full pipeline
- Also known as: EB-1020
- Compare: Centanafadine QD XR vs similar drugs
- Pricing: Centanafadine QD XR cost, discount & access